Literature DB >> 29391231

Inhibiting intimal hyperplasia in prosthetic vascular grafts via immobilized all-trans retinoic acid.

Elaine K Gregory1, Antonio Webb2, Janet M Vercammen1, Megan E Kelly1, Banu Akar3, Robert van Lith4, Edward M Bahnson5, Wulin Jiang1, Guillermo A Ameer6, Melina R Kibbe7.   

Abstract

Peripheral arterial disease is a leading cause of morbidity and mortality. The most commonly utilized prosthetic material for peripheral bypass grafting is expanded pan class="Chemical">polytetrafluoroethylene (ePTFE) yet it continues to exhibit poor performance from restenosis due to neointimal hyperplasia, especially in femoral distal bypass procedures. Recently, we demonstrated that periadventitial delivery of all-trans retinoic acid (atRA) immobilized throughout porous poly(1,8 octamethylene citrate) (POC) membranes inhibited neointimal formation in a rat arterial injury model. Thus, the objective of this study was to investigate whether atRA immobilized throughout the lumen of ePTFE vascular grafts would inhibit intimal formation following arterial bypass grafting. Utilizing standard ePTFE, two types of atRA-containing ePTFE vascular grafts were fabricated and evaluated: grafts whereby all-trans retinoic acid was directly immobilized on ePTFE (atRA-ePTFE) and grafts where all-trans retinoic acid was immobilized onto ePTFE grafts coated with POC (atRA-POC-ePTFE). All grafts were characterized by SEM, HPLC, and FTIR and physical characteristics were evaluated in vitro. Modification of these grafts, did not significantly alter their physical characteristics or biocompatibility, and resulted in inhibition of intimal formation in a rat aortic bypass model, with atRA-POC-ePTFE inhibiting intimal formation at both the proximal and distal graft sections. In addition, treatment with atRA-POC-ePTFE resulted in increased graft endothelialization and decreased inflammation when compared to the other treatment groups. This work further confirms the biocompatibility and efficacy of locally delivered atRA to inhibit intimal formation in a bypass setting. Thus, atRA-POC-ePTFE grafts have the potential to improve patency rates in small diameter bypass grafts and warrant further investigation. Published by Elsevier B.V.

Entities:  

Keywords:  Intimal hyperplasia; Nitric oxide; Peripheral vascular disease; Restenosis; atRA, endothelium

Mesh:

Substances:

Year:  2018        PMID: 29391231      PMCID: PMC5847482          DOI: 10.1016/j.jconrel.2018.01.020

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  33 in total

Review 1.  Retinoid metabolism and its effects on the vasculature.

Authors:  Eun-Jung Rhee; Shriram Nallamshetty; Jorge Plutzky
Journal:  Biochim Biophys Acta       Date:  2011-07-23

Review 2.  Modified prosthetic vascular conduits.

Authors:  Muneera R Kapadia; Daniel A Popowich; Melina R Kibbe
Journal:  Circulation       Date:  2008-04-08       Impact factor: 29.690

3.  All-trans retinoic acid attenuates cardiac allograft vasculopathy in rats.

Authors:  M Zhang; Q Wu; C Shui
Journal:  Transplant Proc       Date:  2010-06       Impact factor: 1.066

Review 4.  Establishment of a rat and guinea pig aortic interposition graft model reveals model-specific patterns of intimal hyperplasia.

Authors:  Elaine K Gregory; Janet M Vercammen; Megan E Flynn; Melina R Kibbe
Journal:  J Vasc Surg       Date:  2016-01-09       Impact factor: 4.268

5.  Therapeutic effect of retinoic acid on unilateral ureteral obstruction model.

Authors:  Kazuya Kishimoto; Koji Kinoshita; Shoichi Hino; Tomohiro Yano; Yasuaki Nagare; Hideki Shimazu; Yuji Nozaki; Masafumi Sugiyama; Shinya Ikoma; Masanori Funauchi
Journal:  Nephron Exp Nephrol       Date:  2011-01-13

6.  Increased blood flow inhibits neointimal hyperplasia in endothelialized vascular grafts.

Authors:  T R Kohler; T R Kirkman; L W Kraiss; B K Zierler; A W Clowes
Journal:  Circ Res       Date:  1991-12       Impact factor: 17.367

7.  Proof of fallout endothelialization of impervious Dacron grafts in the aorta and inferior vena cava of the dog.

Authors:  Q Shi; M H Wu; N Hayashida; A R Wechezak; A W Clowes; L R Sauvage
Journal:  J Vasc Surg       Date:  1994-10       Impact factor: 4.268

Review 8.  Role of Retinoic Acid-Metabolizing Cytochrome P450s, CYP26, in Inflammation and Cancer.

Authors:  Faith Stevison; Jing Jing; Sasmita Tripathy; Nina Isoherranen
Journal:  Adv Pharmacol       Date:  2015-05-27

9.  Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis.

Authors:  Byung Ha Lee; Hye Yeong Nam; Taegun Kwon; Sung Joo Kim; Ghee Young Kwon; Hyun Jung Jeon; Hyun Jung Lim; Woo Kyoung Lee; Jong-sang Park; Jai Young Ko; Dae Joong Kim
Journal:  Nephrol Dial Transplant       Date:  2006-03-22       Impact factor: 5.992

10.  Retinoid receptor expression and all-trans retinoic acid-mediated growth inhibition in vascular smooth muscle cells.

Authors:  J M Miano; S Topouzis; M W Majesky; E N Olson
Journal:  Circulation       Date:  1996-05-15       Impact factor: 29.690

View more
  3 in total

Review 1.  Engineering multifunctional bioactive citrate-based biomaterials for tissue engineering.

Authors:  Min Wang; Peng Xu; Bo Lei
Journal:  Bioact Mater       Date:  2022-05-07

2.  Histopathological evaluation of a retinoic acid eluting stent in a rabbit iliac artery model.

Authors:  Ioanna Samara; Christos S Katsouras; Arsen Semertzioglou; Athanassios Vratimos; Amalia I Moula; Constantinos A Dimitriou; Michail Theofanis; Triantafyllia Papadimitropoulou; Vasileios Bouratzis; Georgia Karanasiou; Dimitrios Fotiadis; Lampros K Michalis; Anargyros N Moulas
Journal:  Sci Rep       Date:  2022-08-03       Impact factor: 4.996

3.  In Vivo Stability of Polyurethane-Based Electrospun Vascular Grafts in Terms of Chemistry and Mechanics.

Authors:  Alexander A Gostev; Inna K Shundrina; Vitaliy I Pastukhov; Alexey V Shutov; Vera S Chernonosova; Andrey A Karpenko; Pavel P Laktionov
Journal:  Polymers (Basel)       Date:  2020-04-07       Impact factor: 4.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.